J&J #Pharma Earnings Up 18.7% Despite Being Top Fined Drug Company! Thanks to high-margin, low-cost Olysio for Hep C | Pharmaguy's Insights Into Drug Industry News | Scoop.it

For the quarter, Johnson & Johnson announced that it produced $18.47 billion in sales, up 5.1% from the previous year (sales were up 5.8% and affected negatively by currency translation) as its net earnings jumped to $4.3 billion, or roughly 10%, to $1.50 per share.

The big factor for J&J which continues to ignite its results is its pharmaceutical sales. Even though its consumer products and medical device and diagnostic segment combine for more in total sales than its pharmaceutical segment, the margins in its pharma segment absolutely trounce that of the other two, making it by far J&J's cash cow.

For the third quarter, Johnson & Johnson announced an 18.7% increase in pharmaceutical sales, led by a 33.1% increase in the U.S., the world's No. 1 user of pharmaceutical products.